Transmissible spongiform encephalopathy: Current and future therapeutic strategies

Reviews and Research in Medical Microbiology

Volumn 9, Issue 3, 1998, Pages 135-151

  Dealler, S F ^a  

^a BURNLEY GENERAL HOSPITAL   (United Kingdom)

Author keywords

Amphotericin B; Bovine spongiform encephalopathy; Carageenan; Congo red; Creutzfeldt Jakob disease; Diazo dye; Glycosidase inhibitors; Heat shock protein 104; Iododoxyrubicin; Mepartricin; Pentosan polysulphate; Scrapie; Transmissible spongiform encephalopathy

Indexed keywords

4' IODOESORUBICIN; ANTIFUNGAL AGENT; CONGO RED; DIAZO DYE; GLYCOSIDASE INHIBITOR; GLYCOSIDE; HEAT SHOCK PROTEIN; PRION PROTEIN; TRANSFERASE INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; BOVINE SPONGIFORM ENCEPHALOPATHY; CELL CULTURE; CREUTZFELDT JAKOB DISEASE; INCUBATION TIME; NONHUMAN; PRION DISEASE; PRIORITY JOURNAL; REVIEW; UNITED KINGDOM;

EID: 0031840632     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199807000-00003     Document Type: Review

References (90)

1. Anderson RM, Donnelly CA, Furguson NM et al. Transmission dynamics and epidemiology of BSE in cattle. Nature 1996; 382: 779-788.
2. Dealler SF, Kent JT. BSE: an update on the statistical evidence. Br Food J 1995; 97: 3-18.
3. Caughey B, Gregory JR. Sulfated polyanion inhibition of scrapie associated PrP accumulation in cultured cells. J Virol 1993; 67: 643-650.
4. Maffrand JP, Herbert JM, Bernat A et al. Experimental and clinical pharmacology of pentosan polysulfate. Semin Thrombo Hemo 1991; 17: 186-198.
5. Ehlers B, Diringer H. Dextran sulphate 500 delays and prevents mouse scrapie by impairment of agent replication in the spleen. J Gen Virol 1984; 65: 1325-1330.
6. Diringer H, Ehlers B. Chemoprophylaxis of scrapie in mice. J Gen Virol 1991; 72: 457-460.
7. Ladogana A, Casaccia P, Ingrosso L et al. Sulphate polyanions prolong the incubation period of scrapie-infected hamsters. J Gen Virol 1992; 73: 661-665.
8. Kimberlin RH, Wilesmith JW. Bovine spongiform encephalopathy. Epidemiology, low dose exposure and risks. Ann New York Acad Sci 1994; 724: 210-220.
9. Ehlers B, Rudolph R, Diringer H. The reticuloendothelial system in scrapie pathogenesis. J Gen Virol 1984; 65: 423-428.
10. Farquhar CF, Dickinson AG. Prolongation of scrapie incubation period by an injection of dextran sulphate 500 within the month before or after infection. J Gen Virol 1986; 67: 463-473.
11. Kimberlin RH, Walker CA. Suppression of scrapie infection in mice by heteropolyanion-23, dextran sulfate and some other polyanions. Antimicrob Agents Chemother 1986; 30: 409-413.
12. Turner EV, Higginbotham RD. Effect of intravenous carrageenan on immune response and on the reticuloendothelial system. J Reticuloendothel Soc 1979; 26: 763-773.
13. Meri S, Pangburn MK. Regulation of alternative complement activation by glycosaminoglycans: specificity of the polyanion binding site on factor H. Biochem Biophys Res Commun 1994; 198: 52-59.
14. Fischer J, Ricard L, Weiss R. The structure of the heteropolystungstate (NH4)17Na(NaW21Sb9O86). 14H2O. An inorganic cryptate. J Am Chem Soc 1976; 98: 3050-3052.
15. Kimberlin RH, Walker CA. The antiviral compound HPA-23 can prevent scrapie when administered at the time of infection. Arch Virol 1983; 78: 9-18.
16. Kimberlin RH, Walker CA. Antiviral compound effective against experimental scrapie. Lancet 1979; ii: 591-592.
17. Brown P. Chemotherapy of unconventional virus infections of the central nervous system. In: Antiviral Agents: The Development and Assessment of Antiviral Chemotherapy, vol. 2. Boca Raton: CRC Press. 1995 pp 13-28.
18. Baker HF, Ridley RM, Crow TJ. Experimental transmission of an autosomal dominant spongiform encephalopathy: does the infectious agent originate in the human genome? BMJ 1985; 291: 299.
19. Brown P. Biologic and chemotherapeutic forays into the field of unconventional viruses. In: De Clercq E, Walker RT, eds. Targets for Design of Antiviral Agents. New York: Plenum Press. 1984 pp 131-157.
20. Frey-Wyssling A. Macromolecules in Cell Stuctures. Cambridge: Harvard University Press. 1957.
21. Llewellyn DB. An improved sirius red method for amyloid. J Med Lab Technol 1970; 27: 308.
22. Caughey B, Race RE. Potent inhibition of scrapie-associated PrP accumulation by congo red. J Neurochem 1992; 59: 768-771.
23. Ingrosso L, Ladogana A, Pocchiari M. Congo red prolongs incubation period of scrapie-infected hamsters. J Virol 1995; 69: 506-508.
24. Stevens NM, Engle CH, Fisher PB, Mechlinski W, Schaffner CP. In vitro antiherpetic activity of water-soluble amphotericin B methyl ester. Arch Virol 1975; 48: 391-394.
25. Schaffner CP, Plescia OJ, Pontani D et al. Antiviral activity of amphotericin B methyl ester: inhibition of HTLV-III replication in cell culture. Biochem Pharmacol 1986; 35: 4110-4113.
26. Amyx H, Salazar AM, Gajdusek DC, Gibbs Jr CJ. Chemotherapeutic trials in experimental slow virus disease. Neurology 1984; 34 (suppl 1): S149.
27. Pocchiari M, Schmittinger S, Masullo C. Amphotericin B delays the incubation period of scrapie in intracerebrally inoculated hamsters. J Gen Virol 1987; 68: 219-223.
28. Pocchiari M, Casaccia P, Ladogana A. Amphotericin B: a novel class of anti-scrapie drugs. J Infect Dis 1989; 160: 795-802.
29. Demaimay R, Adjou K, Lasmezas C et al. Phamacological studies of a new derivative of amphotericin B, MS-8209, in mouse and hamster scrapie. J Gen Virol 1994; 75: 2499-2503.
30. Xi YG, Ingrosso L, Ladogana A, Masullo C, Pocchiari M. Amphotericin B treatment dissociates in vivo replication of the scrapie agent from PrP accumulation. Nature 1992; 356: 598-601.
31. Carp RI. Scrapie. Unconventional infectious agent. In: Spector S, ed. Neuropathogenic Viruses and Immunity. New York: Plenum Press. 1992 pp 111-136.
32. Pocchiari M, Ingrosso L, Ladogana A. Effect of amphotericin B on different experimental strains of spongiform encephalopathy agent. In: Gibbs Jr CJ, ed. Bovine Spongiform Encephalopathy. The BSE dilemma. New York: Springer Verlag. 1996 pp 271-281.
33. Hope J, Multhaup G, Reekie LJD, Kimberlin RH, Beyereuther K. Molecular pathology of scrapie-associated fibril protein (PrP) in mouse brain affected by the ME7 strain of scrapie. Eur J Biochem 1988; 172: 271-277.
34. Masullo C, Macchi G, Xi YG, Pocchiari M. Fairlure to ameliorate CJD with amphotericin B therapy. J Infect Dis 1992; 165: 784-785.
35. Adjou KT, Demaimay R, Lasmezas C, Deslys J-P, Seman M, Dormont D. MS-8209, a new amphotericin B derivative provides enhanced efficacy in delaying hamster scrapie. Antimicrobial Agents Chemother 1995; 39: 2810-2812.
36. Beringue V, Adjou KT, Demaimay R et al. Polyene antibiotics in experimental transmissible subacute spongiform encephalopathies. Presented at the NATO Advanced Research Workshop, Prions and Brain Diseases in Animals and Humans. Erice, Sicily, August 1996.
37. Berger I, Su L, Spitzner JR, Kang C, Burke TH, Rich A. Molecular structure of the halogenated anti-cancer drug iododoxorubicin complexed with d(TGTACA) and d(CGATCG). Nucl Acids Res 1995; 23: 4488-4494.
38. Edwards DM, Marriri P, Efthymiopoulos C et al. Pharmacokinetics of iododoxorubicin in the rat, dog, and monkey. Drug Metab Dispos 1991; 19: 938-945.
39. Tagliavini F, Salmona M, Giaccone G et al. Prion diseases: PrP peptides, pathogenesis and treatment perspectives. Presented at the NATO Advanced Research Workshop, Prions and Brain Diseases in Animals and Humans. Erice, Sicily, August 1996.
40. Aguzzi A, Brandner S, Raeber A et al. Neurotoxicity and neuroinvasiveness of prions in brain grafts. Presented at the NATO Advanced Research Workshop, Prions and Brain Diseases in Animals and Humans. Erice, Sicily, August 1996.
41. Gabizon R, McKinley MP, Groth DS, Prusiner SB. Proc Natl Acad Sci USA 1988; 85: 651-662.
42. McBride PA, Eikelenboom P, Kraal G, Fraser H, Bruce M. PrP protein is associated with folicular dendritic cells of spleens and lymph nodes in uninfected and scrapie infected mice. J Pathol 1992; 168: 413-418.
43. Outram GW, Dickinson AG, Fraser H. Reduced susceptibility to scrapie in mice after steroid administration. Nature 1974; 249: 855-856.
44. Gajdusek DC. Unconventional viruses and the origin and disappearance of kuru. Science 1977; 197: 943-960.
45. Outram GW, Dickinson AG, Fraser H. Slow encephalopathies, inflammatory responses and arachis oil. Lancet 1975; i: 198-200.
46. Muller WEG, Ushijima H, Schroder H et al. Cytoprotective effect of NMDA receptor antagonists on prion protein (Prionsc)-induced toxicity in rat cortical cell cultures. Eur J Pharmocol Mol Pharmacol 1993; 246: 261-277.
47. Wickner RB, Masison DC. Evidence for two prions in yeast: (URE3) and (PSI). In: Prusiner SB, ed. Prions Prions Prions. Berlin: Springer. 1996 pp 147-160.
48. Coughlan A. Does yeast hold secrets of CJD? New Scientist 17 May 1997; 156: 16.
49. Wickner RB, Masison DC, Edskes H, Maddelein M-L. (PSI) and (URE3) as two prions of yeast: genetic and biochemical evidence. NATO Advanced Research Work-shop, Prions and Brain Diseases in Animals and Humans. Erice, Sicily, August 1996 [Abstract 20].
50. Lindquist S. Interaction of chaperones and prions. Presented at the American Society for Microbiology. 97th General Meeting. Miami, May 1997.
51. Dealler S. Transmissible spongiform encephalopathy (TSE) agents as crystalline forms of the prion protein (PrP) that multiply by allowing normal metabolic forms to join the crystal. Med Hypoth 1991; 36: 131-134.
52. Come JH, Fraser PE, Lansbury PT. A kinetic model for amyloid formation in the prion disease: importance of seeding. Proc Natl Acad Sci USA 1993; 90: 5959-5963.
53. Collinge J, Sidle KCL, Meads J, Ironside J, Hill AF. Molecular analysis of prion strain variation and the aetiology of 'new variant' CJD. Nature 1996; 383: 685-690.
54. Bruce M, Chree A, McConnell I, Foster JD, Pearson G, Fraser H. Transmision of bovine spongiform encephalopathy and scrapie to mice: strain variation and the species barrier. In: Philosophical Transations of the Royal Society of London Series B: Biological Sciences. Molecular Biology of Prion Diseases. London: Royal Society of London. 1994 pp 405-411.
55. Marsh R. Comparison of physicochemical properties of two strains of transmissible mink encephalopathy. Presented at the International Symposium on Prion Diseases at Gottingen, Germany, October 1995.
56. De Armond SJ, Sanches H, Yehiely F, Qiu Y et al. Selective neuronal targeting in prion disease. Neuron 1997; 19: 1337-1348.
57. Taraboulos A, Rogers M, Borchelt DR, McKinley MP et al. Acquisition of protease resistance by prion proteins in scrapie infected cells does not require asparagine-linked glycosylation. Proc Natl Acad Sci USA 1990; 87: 8262-8266.
58. Nash R, Watson AA, Asano N. Polyhydroxy alkaloids that inhibit glycosidases. In: Pelletier SW, ed. Alkaloids: Chemical and Biological Perspectives. Oxford: Elsevier. 1996 pp 344-376.
59. Dealler SF. Alkaloidal glycosidase inhibitors (AGIs) as the cause of sporadic scrapie, and the potential treatment of both transmissible spongiform encephalopathies and human immunodeficiency virus infection. Med Hypoth 1994; 42: 69-75.
60. Watson AA, Nasil RJ, Wormald MR et al. Glycosidase-inhibiting pyrrolidine alkaloids from Hyacinthoides nonscripta. Phytochemistry 1997; 46: 255-259.
61. Nash RJ, Watson AA, Winters AL et al. Novel biologically active alkaloids from British plants. In: Wrighly S, Hayes M, Thomas R, Ewan C, eds. Phytochemical Diversity. Cambridge: Royal Society of Chemistry. 1997 pp 106-114.
62. Hindsgaul O, Kaur KJ, Srivastava G et al. Evaluation of deoxygenated oligosaccharide acceptor analogs as specific inhibitors of glycosyl transferases. J Biol Chem 1991; 266: 17858-17861.
63. Carp RI, Kim YS, Callahan SM. Scrapie-induced alterations in glucose tolerance in mice. J Gen Virol 1989; 70: 827-835.
64. Kocisko DA, Come JH, Priola SA, Caughey B. Cell-free formation of protease-resistant prion protein. Nature 1994; 370: 471-474.
65. Kuroda Y, Kaneoka H, Shibaski H, Yamaguchi M. HLA typing of Japanese patients with CJD: significant association with HLA-DQw3. Ann Neurol 1986; 20: 356-359.
66. Wood JLN, McGill IS, Done SH, Bradley R. Neuropathology of scrapie: a study of the distribution patterns of brain lesions in 222 cases of natural scrapie in sheep, 1982-91. Vet Rec 1997; 140: 167-174.
67. Oppenheimer DR, ed. Scrapie Disease in Sheep. New York: Academic Press, 1983.
68. Pickering Brown SM, Mann DM, Owen F et al. Allelic variations in apolipoprotein E and prion protein genotype related to plaque formation and age of onset in sporadic Creutzfeldt-Jakob disease. Neuroscience Lett 1995; 187: 127-129.
69. Krita K, Manaka H, Kato T, Katagiri T, Sasaki H. A case of CJD with markedly elevated ubiquitin concentration in cerebrospinal fluid. Rinsho Shinkeigaku - Clinical Neurology 1991; 31: 666-668.
70. Lowe J, Mayer RJ, Landon M. Ubiquitin in neurodegenerative diseases (review). Brain Pathol 1993; 3: 55-65.
71. Renkawek K, de Jong WW, Merck KB, Franken CW, van Workum FP, Bosman GJ. Alpha B-crystallin is present in reactive glia in CJD. Acta Neuropathologica 1992; 83: 324-327.
72. Wisniewski HM, Losinsky AS, Moretz RC, Vorbrodt AW, Lassmann H, Carp RI. Increased blood-brain barier permeability in scrapie infected mice. Acta Neuropathologica 1987; 73: 43-42.
73. Dealler SF. The key must fit: macrophages transport prion infection to the central nervous system and may determine the sites of infection within it. Med Hypoth 1997; 49: 213-220.
74. Klein MA, Frigg R, Flechsig E et al. A crucial role for B cells in neuroinvasive scrapie. Nature 1997; 390: 687-690.
75. Dealler SF. Can the spread of BSE and CJD be predicted? In: Ratzan SC, ed. The Mad Cow Crisis. Health and the Public Good. London: UCL Press. 1998 pp 35-50.
76. Mayer RJ, Landon M, Laszlo L, Lennox G, Lowe J. Protein processing in lysosomes: the new therapeutic target in neurodegenerative disease. Lancet 1992; ii: 156-159.
77. Campbell IL, Eddleston M, Kemper P, Oldstone MB, Hobbs MV. Activation of cerebral cytokine gene expression and its correlation with onset of reactive astrocyte and acute-phase response gene expression in scrapie. J Virol 1994; 68: 2383-2387.
78. Braham J. Amantidine in the treatment of Creutzfeldt-Jakob disease (letter). Arch Neurol 1984; 42: 585-586.
79. Tateishi J. Antibiotics and antivirals do not modify experimentally-induced Creutzfeldt-Jakob disease in mice. J Neurol Neurosurg Psychiatry 1981; 44: 723-724.
80. David AS, Grant R, Ballantyne JP. Unsuccessful treatment of Creutzfeldt-Jakob disease with acyclovir. Lancet 1984; i: 512-513.
81. Ververken D, Carton H, Billiau A. Intrathecal administration of interferon in MS patients. In: Karcher D, Lowenthal A, Strosberg AD, eds. Humoral Immunity in Neurological Diseases. New York: Plenum Press. 1979 p 625.
82. Kovanen J, Haltia M, Cantrell K. Failure of interferon to modify Creutzfedt-Jakob disease. BMJ 1980; 280: 902.
83. Korth C, Stierli B, Streit P et al. Prion (PrPsc)-specific epitope defined by a monoclonal antibody. Nature 1997; 390: 74-77.
84. Aguzzi A, Collinge J. Post-exposure prophylaxis after accidental prion inoculation. Lancet 1997; 350: 1519-1520.
85. Dealler S. Post exposure prophylaxis after accidental prion inoculation (letter). Lancet 1998; 351: 600.
86. Creange A, Gray F, Cesaro P, Degos J-D. Pooled plasma derivatives and Creutzfeldt-Jakob disease. Lancet 1996; 347: 482.
87. Morris K. WHO reconsiders risks from Creutzfeldt-Jakob disease. Lancet 1997; 349: 1001.
88. Advisory Committee on Dangerous Pathogens. Precautions for work with human and animal transmissible spongiform encephalopathies. London: HMSO. 1994.
89. Bruce ME, Will RG, Ironside JW et al. Transmissions to mice indicate that 'new variant' CJD is caused by the BSE agent. Nature 1997; 386: 446-449.
90. Aguzzi A, Weissmann C. Prion research: the next frontiers. Nature 1997; 386: 795-798.